Novartis' China plans grew from science roundtables

PharmAsia News sat down with Paul Herrling, head of corporate research at Novartis, and En Li, VP and head of research for Novartis Institutes for BioMedical Research Shanghai, to discuss the massive R&D efforts the company now has underway in China.

Novartis began its involvement in China 10 years ago with discussions with Chinese scientists about traditional Chinese therapeutics and how that fit in with Novartis' effort to develop new compounds using natural ingredients. Now Novartis is budgeting $96 million for a new R&D center in China and plans to make the Chinese market one of its top 10 globally.

- read the story from In Vivo

Related Articles:
R&D spending going gangbusters in China
Novartis maps $100M R&D complex in China

Suggested Articles

Bausch Health is paying $10 million upfront for the option to acquire Allegro Ophthalmics’ eye disease assets, with a promise of $40 million to come.

Anthony Coyle, Ph.D., has signed up to run Repertoire Immune Medicines’ R&D.

The IPO haul will set Kronos up to start a registrational phase 2/3 trial of a first-line AML drug licensed from Bischofberger's former employer.